La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cresco Labs Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Cresco Labs sono diminuiti a un tasso medio annuo di -25.3%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 48.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 26.6%.

Informazioni chiave

-25.3%

Tasso di crescita degli utili

-13.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	23.1%
Tasso di crescita dei ricavi	26.6%
Rendimento del capitale proprio	-43.2%
Margine netto	-23.5%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Cresco Labs Inc. (CSE:CL) Shares Could Be 41% Below Their Intrinsic Value Estimate

Oct 27

Ripartizione dei ricavi e delle spese

Come Cresco Labs guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

CNSX:CL Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Jun 24	735	-172	227
31 Mar 24	747	-155	241
31 Dec 23	756	-176	260
30 Sep 23	767	-339	283
30 Jun 23	786	-234	295
31 Mar 23	806	-211	307
31 Dec 22	825	-212	310
30 Sep 22	842	-65	295
30 Jun 22	848	-326	295
31 Mar 22	841	-318	292
31 Dec 21	806	-320	276
30 Sep 21	750	-360	276
30 Jun 21	687	-73	246
31 Mar 21	573	-105	215
31 Dec 20	463	-102	199
30 Sep 20	345	-76	163
30 Jun 20	231	-98	145
31 Mar 20	168	-64	119
31 Dec 19	124	-43	92
30 Sep 19	101	-20	77
30 Jun 19	78	-14	63
31 Mar 19	57	-12	46
31 Dec 18	41	-2	31
30 Sep 18	28	0	19
30 Jun 18	19	1	9
31 Mar 18	13	1	7
31 Dec 17	10	-3	5
31 Dec 16	3	-8	4

Guadagni di qualità: CL al momento non è redditizia.

Margine di profitto in crescita: CL al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: CL non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 25.3% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di CL nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: CL non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( -19.4% ).

Rendimento del capitale proprio

ROE elevato: CL ha un Return on Equity negativo ( -43.21% ), in quanto al momento non è redditizio.

Cresco Labs Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Recent updates

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%

Insider recently sold CA$157k worth of stock

Consensus EPS estimates fall by 109%

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Now 22% undervalued after recent price drop

Co-Founder & Independent Director recently sold CA$1.7m worth of stock

Forecast breakeven date moved forward to 2023

Forecast breakeven date pushed back to 2024

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021)

Combs Enterprises signed a definitive agreements to acquire Certain New York, Illinois, and Massachusetts assets of Cresco Labs Inc. and Columbia Care Inc. for approximately $190 million.

Price target decreased to CA$10.10

Consensus forecasts updated

Cresco Labs Inc. to Report Q3, 2022 Results on Nov 15, 2022

Cresco Labs Inc. Announces Resignation of Sidney Dillard from the Board of Director

Aventine Property Group, Inc. acquired Cresco Labs Facility in Brookville, PA for $45 million